PAX8 is expressed in the majority of renal epithelial neoplasms: an immunohistochemical study of 223 cases using a mouse monoclonal antibody

Yingchuan Hu,1 Arndt Hartmann,2 Christine Stoehr,2 Shaobo Zhang,1 Mingsheng Wang,1 David Tacha,3 Rodolfo Montironi,4 Antonio Lopez-Beltran,5 Liang Cheng1

ABSTRACT

Aims PAX8 is a cell lineage-specific transcription factor which plays a crucial role in the organogenesis of the kidney, thyroid gland and Mullerian duct. A previous study showed that PAX8 is a specific and sensitive marker for both renal and ovarian carcinomas. The purpose of this study is to investigate PAX8 expression using a new monoclonal PAX8 antibody in a larger number of renal epithelial neoplasms including clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma and renal oncocytoma.

Methods PAX8 immunohistochemical staining was performed on tissue microarrays containing 84 cases of clear cell renal cell carcinoma, 66 cases of chromophobe renal cell carcinoma, 57 cases of papillary renal cell carcinoma and 16 cases of renal oncocytoma. PAX8 expression was detected in 93% (78/84) of cases of clear cell renal cell carcinoma, 66 cases of chromophobe renal cell carcinoma, 57 cases of papillary renal cell carcinoma, 95% (54/57) of cases of papillary renal cell carcinoma and renal oncocytoma, 94% (15/16) of cases of renal oncocytoma.

Results PAX8 expression was detected in 93% (78/84) of cases of clear cell renal cell carcinoma, 80% (53/66) of cases of chromophobe renal cell carcinoma, 95% (54/57) of cases of papillary renal cell carcinoma and 94% (15/16) of cases of renal oncocytoma.

Conclusions PAX8 is expressed in the majority of renal epithelial neoplasms including renal cell carcinomas and oncocytomas and the monoclonal PAX8 antibody is more sensitive than polyclonal antibody to detect chromophobe renal cell carcinoma. These results showed that PAX8 is a valuable marker for nephric neoplasms.

INTRODUCTION

PAX8 is a cell lineage-specific transcription factor which plays a crucial role in the organogenesis of the kidney, thyroid gland and Mullerian duct. Our previous study using a rabbit polyclonal antibody anti-PAX8 in a wide variety of normal and neoplastic tissues showed that PAX8 is a sensitive and specific marker for both renal and ovarian carcinomas.1 While there are several studies including ours on renal cell carcinomas using polyclonal PAX8 antibody immunohistochemistry,2–3 the information for a new monoclonal PAX8 antibody in renal epithelial neoplasms is very limited. Therefore, using a new monoclonal PAX8 antibody, this study aims to investigate PAX8 expression in a larger number (223 cases) of renal epithelial neoplasms including 84 cases of clear cell renal cell carcinoma, 57 cases of papillary renal cell carcinoma, 66 cases of chromophobe renal cell carcinoma and 16 cases of renal oncocytoma.
In this study, using a monoclonal PAX8 antibody, we found that 90% (200/223) of renal epithelial neoplasms were positive for PAX8. Among renal cell carcinomas, papillary renal cell carcinomas had the highest percentage of positivity for PAX8, followed by clear cell renal cell carcinomas and chromophobe renal cell carcinomas. Most renal oncocytomas were positive for PAX8. These findings confirm earlier studies by us and other groups using a polyclonal PAX8 antibody and further show that PAX8 is a very useful immunomarker for renal epithelial neoplasm.1

PAX8 is one of the nine members of the paired box (PAX) family of cell lineage transcription factors, which play crucial roles during fetal development and neoplastic growth.3–7 PAX8 is a nephric lineage nuclear transcription factor which plays an important role in renal organogenesis.3 10–14 PAX8 may also be involved in maintaining the differentiated features and specialised functions of renal epithelial cells.15 16 Our previous study, using a rabbit polyclonal PAX8 antibody, found PAX8 positivity in 91% (86/94) of clear cell renal cell carcinomas, 100% (14/14) of papillary renal cell carcinomas and 57% (4/7) of chromophobe renal cell carcinomas.1 The current study with a mouse monoclonal antibody showed that 93% of clear cell renal cell carcinomas, 95% of papillary renal cell carcinomas and 80% of chromophobe renal cell carcinomas were positive for PAX8. These findings are similar to those from other groups and our previous study using polyclonal PAX8 antibody with the exception of a lower positive rate for chromophobe renal cell carcinoma (57% vs 80%). The lower positive rate in our previous study may be due to the limited number (only seven cases) of chromophobe renal cell carcinomas. Our current study, which consisted of a larger number of cases, further confirmed our previous findings that chromophobe renal cell carcinoma has the lowest PAX8 positive rate among the common renal cancers.1 These findings are consistent with those reported by Laury et al.2

Using a polyclonal PAX8 antibody, Laury et al found that 93% (115/123) of clear cell renal cell carcinomas, 76% (19/25) of papillary renal cell carcinomas, 80% (4/5) of chromophobe renal cell carcinomas and 81% (13/16) of renal oncocytomas were positive for PAX8.

### Table 1 Summary of PAX8 immunostaining in renal epithelial neoplasms

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Negative (%)</th>
<th>Positive (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear cell renal cell carcinoma</td>
<td>84</td>
<td>6 (7)</td>
<td>78 (93)</td>
</tr>
<tr>
<td>Chromophobe renal cell carcinoma</td>
<td>66</td>
<td>13 (20)</td>
<td>53 (80)</td>
</tr>
<tr>
<td>Papillary renal cell carcinoma</td>
<td>57</td>
<td>3 (5)</td>
<td>54 (95)</td>
</tr>
<tr>
<td>Renal oncocytoma</td>
<td>16</td>
<td>1 (6)</td>
<td>15 (94)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>223</td>
<td>23 (10)</td>
<td>200 (90)</td>
</tr>
</tbody>
</table>

Figure 1 Immunohistochemical staining of PAX8 in renal epithelial neoplasms. Positivity for PAX8 was seen in clear cell renal cell carcinoma (A), papillary renal cell carcinoma (B), chromophobe renal cell carcinoma (C) and renal oncocytoma (D) (magnification 200×).
positive for PAX8.\textsuperscript{2} Similarly, using a polyclonal PAX8 antibody, Tong \textit{et al} detected PAX8 positivity in 98\% (58/59) of clear cell renal cell carcinomas, 90\% (19/21) of papillary renal cell carcinomas, 82\% (9/11) of chromophobe renal cell carcinomas and 98\% (21/22) of renal oncocytomas.\textsuperscript{3} Our findings are very similar to those reported by Laury \textit{et al} and Tong \textit{et al}, with the exception of a slightly higher positive rate (95\%) in papillary renal cell carcinomas in our current study of 223 cases of renal tumours.\textsuperscript{2,3}

Tissue microarray immunohistochemistry is a very useful screening tool to identify promising biomarkers.\textsuperscript{4–5} However, its limitation should be realised as the positive rate in the current study may be underestimated when dealing with heterogeneous expressions, such as PAX8. Previous studies by our group and other groups have shown that the concordance between tissue microarray and whole section is over 90\% as representative areas based on whole section reviews were preselected to construct the tissue microarray. Our results in the current study are similar to those reported by other groups.\textsuperscript{1–5}

In summary, our results in the 223 cases of renal epithelial neoplasms showed that PAX8 is expressed in a high percentage (90\%) of renal neoplasms including both malignant renal tumours (renal cell carcinomas, 80–95\%) and benign renal tumours (oncocytomas, 94\%), which in turn confirm that PAX8 is a valuable marker for nephric tumours.

**Take-home messages**

- PAX8 is a cell lineage-specific transcription factor which plays a crucial role in the organogenesis of the kidney, thyroid gland and Müllerian duct.
- PAX8 is expressed in the majority of renal epithelial neoplasms.
- Chromophobe renal cell carcinoma has a lower PAX8 positive rate among the common renal tumour types.

**Competing interests** None.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**REFERENCES**


PAX8 is expressed in the majority of renal epithelial neoplasms: an immunohistochemical study of 223 cases using a mouse monoclonal antibody

Yingchuan Hu, Arndt Hartmann, Christine Stoehr, Shaobo Zhang, Mingsheng Wang, David Tacha, Rodolfo Montironi, Antonio Lopez-Beltran and Liang Cheng

*J Clin Pathol* 2012 65: 254-256 originally published online December 1, 2011
doi: 10.1136/jclinpath-2011-200508

Updated information and services can be found at:
[http://jcp.bmj.com/content/65/3/254](http://jcp.bmj.com/content/65/3/254)

**References**

This article cites 15 articles, 3 of which you can access for free at:
[http://jcp.bmj.com/content/65/3/254#BIBL](http://jcp.bmj.com/content/65/3/254#BIBL)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Urological cancer (164)
- Immunology (including allergy) (1652)
- Gynecological cancer (184)

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)